Veröffentlichungsdatum: 10 Juli 2019
Projektträger – zwischengeschaltetes Finanzinstitut
The promoter is a pharmaceutical company developing a novel short-acting anaesthetic compound. The eligible investment plan includes research and development (R&D) and related expenses to finance the development and regulatory filing of the drug, including the costs associated with a paediatric formulation of the product.
The proposed transaction will support R&D investments required to advance the promoter's product pipeline and bring the products to market.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 20 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 69 million
The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Unterzeichnet - 28/06/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).